NCT04891198View on ClinicalTrials.gov

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

August 30, 2027

Study Completion Date

April 30, 2028

Conditions

Solid Tumor

Interventions

DRUG

Envafolimab

Subcutaneous injection

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY